Effect of Cariprazine versus Aripiprazole on Cardiometabolic Profile in Patients with Schizophrenia Switched from Olanzapine due to Weight gain: A Randomized Controlled Trial - NI

All India Institute of Medical Sciences Patna0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•Patient diagnosed with Schizophrenia who had received olanzapine monotherapy at a dose of 5 to 20 mg per day for a minimum 4 weeks before inclusion
•Either gender
•Age between 18 to 65 years
•Significant weight gain greater than or equal to 7 percent during prior olanzapine therapy to be verified by medical record
•Increase in weight less than 7 percent with less than 20 percent decrease in Positive and Negative Syndrome Scale score during prior olanzapine therapy for minimum of 4 weeks
•Patients willing to give informed consent for the therapeutic intervention and to participate in the study

•Patients who previously failed to respond to an adequate course of Aripiprazole (10mg to 30mg per day for greater than equal to 4 weeks) or Cariprazine (1.5 to 6 mg per day for greater than equal to 4 weeks)
•Other Schizophrenia spectrum disorders
•Highly agitated, suicidal patients who need immediate treatment
•Co-morbid axis I psychiatric illness
•Patients with co-morbid substance abuse except Nicotine use
•Pregnant and nursing women
•Patients with known history of diabetes mellitus- HbA1C greater than 6.5 percent,
•Patients with known history of hypertension-Blood Pressure greater than equal to 130 mm Hg systolic pressure and 85 mm Hg diastolic Pressure Patients with known history of significant neurological impairment
•Patient with clinical observable mental retardation
•History of organicity that precludes participation in study

发起方

All India Institute of Medical Sciences Patna